CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer

Abstract Background Cardiovascular (CV) comorbidities and concurrent medications with risk of heart rate-corrected QT interval (QTc) prolongation can impact treatment decisions and safety discussions for patients with breast cancer. However, limited data are available regarding their prevalence in p...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan Dent, Avirup Guha, Heather Moore, Doris Makari, Rachael McCaleb, Irene Arias, Stella Stergiopoulos, Benjamin Li, Michael Fradley
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Cardio-Oncology
Subjects:
Cardiovascular comorbidities
Cyclin-dependent kinase 4/6 inhibitor
HR + /HER2–
Medical claims
Metastatic breast cancer
QTc prolongation
Online Access:https://doi.org/10.1186/s40959-025-00305-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00305-w

Similar Items